Enter your Email Address


Useful Links

Know What The Insiders Are Doing!
Stock Trading Software

More Links




[Most Recent Quotes from www.kitco.com]

[Most Recent Quotes from www.kitco.com]




GameStop Meets Expectations – Analyst Blog

Zacks Market Commentaries (November 20th, 2009) Writes:
GameStop Corporation (GME) the biggest video game retailer, reported third quarter earnings of 32 cents per share, slightly above the Zacks Consensus Estimate of 31 cents. The reported earnings were 6% lower than prior-year quarter. Revenue for the quarter increased 8.2% to $1,834.7 million compared to $1,695.7 million reported in the year-ago quarter. The company’s top-line benefited from strong new title releases and price cuts on all current generation platforms. While new software sales grew 9.4%, used product sales increased 19.4% during the quarter. However, comparable store sales dropped 7.8% due to a decline in new video game hardware sales. New video game hardware sales fell 2%. The company opened 86 stores during the quarter, including 48 in the U.S. Gross margin increased 60 basis points year-over-year to 28.5% in the reported quarter. The margin improvement was a result of product mix shift from low-margin ...

Pozen Initiates New Phase III – Analyst Blog

Zacks Market Commentaries (November 20th, 2009) Writes:
This morning, Pozen (POZN) initiated phase III studies on PA-325/40, a fixed-dose combination of 325mg enteric coated aspirin and 40mg of immediate release omeprazole. The phase III program will consist of two pivotal trials conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. FDA, and one long-term safety study. The two pivotal programs will enroll approximately 500 patients per study at over 100 sites around the U.S. The primary endpoint of the pivotal studies is the cumulative incidence of gastric ulcers over the six-month treatment period for PA32540 versus 325 mg of enteric-coated aspirin. The long-term study will enroll approximately 400 patients and assess safety over a period of one year. Pozen is developing PA-325/40 for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers. Aspirin is the No. 1 recommended agent for at-risk ...

TreeHouse Enters Oversold Territory – Zacks Tale of the Tape

Zacks Market Commentaries (November 20th, 2009) Writes:
TreeHouse Foods Inc.’s (THS) share price has entered into oversold territory with a stochastic value of 11.30. Analysts have been increasing their estimates on the company’s full-year earnings, sending the Zacks Consensus Estimate up by 4 cents over the past month to $2.10 per share. TreeHouse Foods is a Zacks #2 Rank (“Buy") company."THS" Free Stock Analysis: Buy? Sell? Hold?Zacks Investment Research

Bearish MACD for Entertainment Properties – Zacks Tale of the Tape

Zacks Market Commentaries (November 20th, 2009) Writes:
Entertainment Properties Trust’s (EPR) MACD indicator has moved into bearish territory with a reading of -0.6341. The Zacks #4 Rank (“Sell") stock fell slightly to $30.83 in afternoon trade. The Zacks Consensus Estimate on the company’s full-year earnings has decreased by 7 cents over the past month to $3.38 cents per share."EPR" Free Stock Analysis: Buy? Sell? Hold?Zacks Investment Research

ADC Dips on Weak Outlook – Analyst Blog

Zacks Market Commentaries (November 20th, 2009) Writes:
Yesterday, after market close, ADC Telecommunications Inc. (ADCT) declared financial results for the fourth quarter of fiscal 2009. Earlier, the Board of Directors of ADC had taken a decision to change its fiscal year from Oct 31 to Sep 30. As a result, fiscal year 2009 ended on Sep 30, 2009, which means the company got only two months as its fourth quarter. The fourth quarter of fiscal 2009 would, therefore, not be comparable to either the prior-year quarter or the previous quarter. For this reason, management has presented pro forma results for the three month period ending Sep 30 and its comparable quarter.   Actual revenue of fourth quarter 2009 was $183.9 million, below the Zacks Consensus Estimate of $189 million. Quarterly pro forma revenue was $293.6 million, down 17.5% year-over-year. This significant decline in revenue is the result of the global economic recession across all the ...

Jones Apparel Enters Oversold Territory – Zacks Tale of the Tape

Zacks Market Commentaries (November 20th, 2009) Writes:
Jones Apparel Group Inc.’s (JNY) share price has entered into oversold territory with a stochastic value of 15.69. The Zacks Consensus Estimate on the Zacks #1 Rank (“Strong Buy") company’s full-year earnings has increased by 3 cents over the past week to $1.11 per share. The most accurate estimate is even bullish at $1.16 per share."JNY" Free Stock Analysis: Buy? Sell? Hold?Zacks Investment Research

Bearish MACD for Inland Real Estate – Zacks Tale of the Tape

Zacks Market Commentaries (November 20th, 2009) Writes:
Inland Real Estate Corp.’s (IRC) MACD indicator has moved into bearish territory with a reading of -0.0285. The Zacks #5 Rank (“Strong Sell") stock declined nearly 1% to $8.05 in morning trade. The Zacks Consensus Estimate on the company’s full-year earnings has reduced by 17 cents over the past month to 88 cents per share."IRC" Free Stock Analysis: Buy? Sell? Hold?Zacks Investment Research

AstraZeneca Seeks FDA Approval – Analyst Blog

Zacks Market Commentaries (November 20th, 2009) Writes:
Recently, AstraZeneca plc (AZN) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its blood clot preventer Brilinta (ticagrelor). Brilinta is an oral reversible P2Y12 adenosine diphosphate receptor antagonist for arterial thrombosis aimed to compete with the blockbuster drug Plavix which is co-developed by Bristol-Myers Squibb (BMY) and Sanofi-Aventis (SNY). On Oct 26, 2009, AstraZeneca filed for approval of the drug with the European Medicines Agency (EMEA) and is awaiting validation of the application.   AstraZeneca is seeking an FDA approval of Brilinta primarily on the basis of data from PLATO (a study of Platelet Inhibition and Patient Outcomes), a late-stage 18,624 patient trial, that showed that Brilinta was more effective than Plavix in treating patients with acute coronary syndrome (ACS) in 43 countries. Brilinta treatment resulted in a reduction of cardiovascular events (CV death, MI or ...

Limited Brands Raises Guidance – Analyst Blog

Zacks Market Commentaries (November 20th, 2009) Writes:

Limited Brands Inc. (LTD) reported results for the third quarter of fiscal 2009 with earnings of 2 cents per share. Earnings were below the Zacks Consensus Estimate of 6 cents but were up 50% compared to the prior-year quarter.   Net sales for the quarter declined 3.5% year-over-year to $1.7 billion due to a 2% decline in comparable same store sales (comps).   According to channels, comparable same store sales of Victoria’s Secret channel contracted 4% as bra sales rose only modestly by low single-digits, while panties sales were down low single-digits. However, beauty sales were flat year-over-year as declines were fully offset by new launches and the strong performance of core products.   Bath & Body Works channel’s comparable store sales increased 2% during the quarter. The channel benefited from the improvement in the merchandise margin rate.   Gross margin for the quarter expanded 16 basis points

...

China Mobile Outlines 4G Plan – Analyst Blog

Zacks Market Commentaries (November 20th, 2009) Writes:

China Mobile (CHL), the world’s largest wireless carrier by subscriber, has revealed its plan to commence the trial run of its 4G network during World Expo 2010 to be held in Shanghai from May 1 to Oct 31, 2010. The company’s 4G service is based on the TD-LTE (Time Division Duplex Long Term Evolution) mobile broadband technology. Roughly 200 participants and 70 million visitors are expected to assemble at the Expo.   China Mobile has recently selected Alcatel-Lucent (ALU) for the responsibilities of design, construction, installation and integration of communication infrastructure to facilitate the 4G network trial. The TD-LTE network will provide advanced wireless services (including high-definition TV and ultra-fast broadband Internet access) to the visitors at the exposition.   The three major Chinese telecom operators China Mobile, China Unicom (CHU) and China Telecom (CHA) are investing heavily in Shanghai to improve the city’s network

...

Newsletter

No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.